HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women

Bookmark and Share
Published: 7 Dec 2017
Views: 1302
Prof Debu Tripathy - MD Anderson Cancer Center, Houston, USA

Prof Tripathy speaks at a SABCS 2017 press session about data from the MONALEESA-7 phase III clinical trial.

Adding the CDK4/6 inhibitor ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival for pre- and perimenopausal women with advanced hormone receptor–positive (HR-positive), HER2-negative breast cancer.

Read the news story for more.